Project Grant R01CA299298
Award Date 7/10/26
Completion Date 6/30/31
Dollars Obligated $545K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85724, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Arizona a $544,929 Project Grant under the Cancer Biology Research program (CFDA 93.396) for a five-year research initiative commencing June 1, 2026, and concluding May 31, 2031. The research investigates the role of estrogen receptor (ER) in regulating breast cancer cell invasion, with particular focus on how tumor microenvironment (TME) components—specifically matrix stiffness and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $588,677 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona, with an award date of July 1, 2026, and a project completion date of June 30, 2031. The research focuses on identifying the mechanisms by which oxygen-dependent centrosome instability drives prostate cancer progression. Specifically, the project investigates how hypoxia induces centrosome loss and...
- Federal Project Grant Award Summary New York University School of Medicine received a $585,482 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 31, 2031. This five-year research award funds fundamental investigation into the molecular mechanisms of breast cancer metastasis, specifically examining the role of the translation initiation factor DAP5 (Death-Associated Protein 5) in selective...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $1.15 million Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded August 11, 2025, with completion targeted for July 31, 2030. This research initiative, titled "The Integrated Mechanobiology and Glycobiology of Bone Metastasis," addresses fundamental gaps in understanding how breast cancer cells colonize and evade immune...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $930,500 under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona to support a seven-year project (September 10, 2025 – August 31, 2032) investigating loss of Y chromosome (LOY) in cancer development and progression. The research focuses on understanding why loss of the Y chromosome in both cancer cells and immune cells within the tumor microenvironment drives aggressive bladder cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $687,291 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award funds fundamental research to elucidate molecular mechanisms by which cancer driver mutations suppress antitumor immune responses, specifically focusing on the role of MLL3 (KMT2C) mutations in promoting regulatory T cell (Treg)...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Southern California $479,234 under the Cancer Biology Research program (CFDA 93.396) on May 15, 2026, to conduct fundamental research on nonsense-mediated mRNA decay (NMD) mechanisms in cancer. The project, which extends through April 30, 2031, will deliver integrated computational and statistical analyses leveraging multi-omics data from the Cancer Genome Atlas (TCGA) and the Dependency Map (DepMap) to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a Project Grant of $448,017 under the Cancer Biology Research program (CFDA 93.396) on August 1, 2026, for a five-year project period through July 31, 2031. The award funds research to elucidate mechanisms enabling HER2-positive (HER2+) breast cancer cells to colonize and thrive in the brain, where brain metastases develop in over half of HER2+ breast cancer patients and...